Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal CancerBusiness Wire • 12/18/25
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast CancerBusiness Wire • 12/16/25
Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks24/7 Wall Street • 12/11/25
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast CancerBusiness Wire • 12/11/25
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual MeetingBusiness Wire • 12/03/25
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer SymposiumBusiness Wire • 12/02/25
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech StocksThe Motley Fool • 11/30/25
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He's Buying Now.24/7 Wall Street • 11/24/25
Natera, Inc. (NTRA) Presents at 7th Annual Wolfe Research Healthcare Conference TranscriptSeeking Alpha • 11/20/25
Natera, Inc. (NTRA) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/19/25
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% SpecificityBusiness Wire • 10/28/25
Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their RightsBusiness Wire • 10/27/25